Two Research Reports on How Trehalose Benefits Bipolar, Sanfillipo Syndrome and Muscular Dystrophy – By JC Spencer

by | Mar 18, 2020

Two Research REPORTS on how Trehalose Benefits

Bipolar, Sanfillipo Syndrome, and Muscular Dystrophy

 

Glycoscience NEWS Lesson #3 for 2020

by JC Spencer

January 2020 – A biopharmaceutical company asked for US and EU government approval for additional testing of the sugar Trehalose for neurological benefits including Sanfillipo syndrome. They reference success in other neurological diseases including muscular dystrophy. Meanwhile, a paper has just been published of the results of studies conducted on Trehalose at the Barcelona University in Spain.

Ongoing research on bipolar disorders is to determine the efficacy and safety of antidepressant drug treatment. Current evidence for the use of antidepressant drugs is lacking even when combined with mood stabilizers. There is a world-wide need to discover a better way to treat depression and specifically bipolar depression.

The sugar Trehalose protects cells from hypoxic and anoxic injury and suppresses protein aggregation. The misfolding of proteins is the cause of or the accentuation of all neurological challenges including Alzheimer’s, Parkinson’s, ALS, and MS.

In vivo studies Trehalose showed cellular and behavioral beneficial effects in animal models of neurodegenerative diseases. Trehalose also provided enhanced autophagy and appeared to have antidepressant results that induce positive behavioral changes.

Trehalose also increases the lithium effects in mice. Based on this hypothesis, the University of Barcelona bipolar project plans to conduct a followup study to determine the efficacy and tolerability of the sugar Trehalose to treat bipolar depression.

The biopharmaceutical company, Seelos Therapeutics is seeking development of therapeutic drugs to address central nervous system disorders and rare diseases. They announced an update to its development programs for SLS-005 (trehalose) in Europe and the U.S.

“We are truly excited to be working with the EMA to formulate the Sanfilippo study in the EU”, said Raj Mehra, Ph.D., Chairman and CEO of Seelos, “there are currently no approved therapies in the EU for this devastating neurological condition.”

In 2018 researchers at the Baylor College of Medicine in Houston said their study was the first report of where THE TREHALOSE EFFECT is quantified for the amount of Trehalose that crosses the blood-brain barrier and activates TFEB (a transcription factor master regulator) in the brain. In turn, TFEB activated the lysosomal system, which led to enhanced clearance of material accumulation, reduced neuroinflammation, retinal degeneration and vision loss and extended lifespan. The retina improvement is significant because loss of vision is a devastating aspect of lysosomal diseases.

References:

https://clinicaltrials.gov/ct2/show/NCT02800161

https://finance.yahoo.com/news/seelos-therapeutics-announces-updates-sls-123010476.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAHtzGRRSfSnbcL1R1wTZv7c85TSIetTOhF8iaFxe_wNTexFj6mOX21DSjIbl7N8DEYau8GP9ERkLAcOSqiuQef6B14CNH1niRNYEn8nvxj3EgTgwDTtNL7V4SN0-sCi8Wto0_0Oy2EjBPch2UitsNs-GfOC104p8YAxEhDGzlKR1

Note: Past and present Lessons and Articles are migrating to
http://TexasEndowment.org

Glycoscience 101 from Amazon or our bookstore

To Kill A Rat from Amazon or http://ToKillARatBOOK.com

http://www.OneSmartSugar.com 

Sponsored in part by Sweet Yet Healthy Corporation  http://TryX5.com

© Copyrighted 2020 by JC Spencer

Contact:   [email protected]

Texas Endowment for Medical Research, Inc.
PO Lock Box 73089, Houston, Texas 77273
http://TexasEndowment.org    281-587-2020

Pin It on Pinterest

Share This